Testing Results of the BioOdyssey Calligrapher MiniArrayer for Clinical Research Available
News Nov 08, 2007
Bio-Rad Laboratories, Inc. has announced the availability of a technical bulletin (bulletin 5534A), that describes results of the testing of the BioOdyssey™ Calligrapher™ MiniArrayer, which is used for the printing of protein microarrays.
The widespread application of microarray technology to clinical research and clinical trials requires the ability to assess the technical and quality aspects of robotic devices that are used to construct the arrays.
Instruments approved for use in human clinical diagnostic laboratories must undergo extensive quality assessments, including documentation of accuracy, precision, linearity, and sensitivity for a given assay. As in a clinical setting, it is necessary to understand the capabilities and limitations of a robotic microarray printing device.
Bio-Rad’s bulletin 5534A provides an analysis of the issues associated with microarray printing and offers testing results of the BioOdyssey Calligrapher MiniArrayer that can be used to assess microarray printing results.
Along with a detailed introduction, the six-page bulletin uses diagrams, tables, and graphics to provide an extensive description of methods used in the evaluation.
Results of the evaluation confirm that the BioOdyssey Calligrapher MiniArrayer is technically capable to print reverse-phase microarrays (RPPAs) in batches up to 16 slides. Inter- and intra-slide CVs were <10% as evidenced through printing standard curves in replicates.
Ancient Fish Genes May Hold Key to Spinal Cord RepairNews
A study has found that genes controlling spinal cord repair in the lamprey fish are also active in mammals, which could provide a blueprint for treatment.READ MORE
Prostate Tumor Progression Dictated by Cancer’s Gene-determined “Immune Landscape”News
The field of immunotherapy is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.READ MORE